Edition:
United States

Alere Inc (ALR_pb.N)

ALR_pb.N on New York Stock Exchange

343.00USD
19 Sep 2016
Change (% chg)

-- (--)
Prev Close
$343.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
644
52-wk High
$406.88
52-wk Low
$255.75

ALR_pb.N

Chart for ALR_pb.N

About

Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals... (more)

Overall

Beta: 1.12
Market Cap(Mil.): $3,750.65
Shares Outstanding(Mil.): 86.74
Dividend: --
Yield (%): --

Financials

  ALR_pb.N Industry Sector
P/E (TTM): -- 46.41 36.60
EPS (TTM): -1.06 -- --
ROI: -1.63 7.61 13.91
ROE: -6.22 9.74 14.82

Abbott, Alere agree to mediate merger dispute

Medical device maker Abbott Laboratories and Alere Inc agreed on Thursday to work with a mediator to settle their dispute over Abbott's role in obtaining U.S. antitrust clearance for its $5.8 billion takeover of the diagnostics company, but Alere voiced concern about the speed of the process.

Sep 08 2016

Abbott, Alere agree to mediate merger dispute

Medical device maker Abbott Laboratories and Alere Inc agreed on Thursday to work with a mediator to settle their dispute over Abbott's role in obtaining U.S. antitrust clearance for its $5.8 billion takeover of the diagnostics company, but Alere voiced concern about the speed of the process.

Sep 08 2016

Abbott, Alere agree to mediate merger dispute

Sept 8 Medical device maker Abbott Laboratories and Alere Inc agreed on Thursday to work with a mediator to settle their dispute over Abbott's role in obtaining U.S. antitrust clearance for its $5.8 billion takeover of the diagnostics company, but Alere voiced concern about the speed of the process.

Sep 08 2016

Delaware judge expedites Alere lawsuit against Abbott

NEW YORK/WILMINGTON, Del. A Delaware judge on Friday granted a motion to expedite Alere Inc's lawsuit against Abbott Laboratories , which seeks to ensure that Abbott lives up to the terms of its $5.8 billion takeover of the diagnostics company, representatives for Alere said.

Sep 02 2016

Delaware judge expedites Alere lawsuit against Abbott

NEW YORK/WILMINGTON, Del. A Delaware judge on Friday granted a motion to expedite Alere Inc's lawsuit against Abbott Laboratories, which seeks to ensure that Abbott lives up to the terms of its $5.8 billion takeover of the diagnostics company, representatives for Alere said.

Sep 02 2016

UPDATE 1-Delaware judge expedites Alere lawsuit against Abbott

NEW YORK/WILMINGTON, Del., Sept 2 A Delaware judge on Friday granted a motion to expedite Alere Inc's lawsuit against Abbott Laboratories, which seeks to ensure that Abbott lives up to the terms of its $5.8 billion takeover of the diagnostics company, representatives for Alere said.

Sep 02 2016

Delaware Judge expedites Alere lawsuit against Abbott

NEW YORK, Sept 2 A Delaware judge on Friday granted a motion to expedite Alere Inc's lawsuit against Abbott Laboratories, which seeks to ensure that Abbott lives up to the terms of its $5.8 billion takeover of the diagnostics company, representatives for Alere said.

Sep 02 2016

Alere lawsuit accuses Abbott of 'buyer's remorse' in proposed merger

Alere Inc alleges Abbott Laboratories is trying to stymie its planned $5.8 billion takeover of the diagnostics company by purposefully delaying key submissions to anti-trust regulators, according to a lawsuit made public on Tuesday.

Aug 31 2016

Alere lawsuit accuses Abbott of 'buyer's remorse' in proposed merger

Alere Inc alleges Abbott Laboratories is trying to stymie its planned $5.8 billion takeover of the diagnostics company by purposefully delaying key submissions to anti-trust regulators, according to a lawsuit made public on Tuesday.

Aug 31 2016

CORRECTED-Alere lawsuit accuses Abbott of 'buyer's remorse' in proposed merger

Aug 31 Alere Inc alleges Abbott Laboratories is trying to stymie its planned $5.8 billion takeover of the diagnostics company by purposefully delaying key submissions to anti-trust regulators, according to a lawsuit made public on Tuesday.

Aug 31 2016

Competitors

Earnings vs. Estimates